Mologni L - Search Results

1

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.

Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L. Arosio G, et al. Among authors: mologni l. Cancers (Basel). 2021 Sep 1;13(17):4422. doi: 10.3390/cancers13174422. Cancers (Basel). 2021. PMID: 34503232 Free PMC article.

2

Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene.

Mologni L, leCoutre P, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Nucleic Acids Res. 1998 Apr 15;26(8):1934-8. doi: 10.1093/nar/26.8.1934. Nucleic Acids Res. 1998. PMID: 9518485 Free PMC article.

3

In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.

Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398

4

Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.

Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Cancer Res. 2001 Jul 15;61(14):5468-73. Cancer Res. 2001. PMID: 11454693

5

Expression, purification, and inhibition of human RET tyrosine kinase.

Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236

6

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.

Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Donella-Deana A, et al. Among authors: mologni l. Biochemistry. 2005 Jun 14;44(23):8533-42. doi: 10.1021/bi0472954. Biochemistry. 2005. PMID: 15938644

7

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L. Gunby RH, et al. Among authors: mologni l. J Med Chem. 2006 Sep 21;49(19):5759-68. doi: 10.1021/jm060380k. J Med Chem. 2006. PMID: 16970400

8

Inhibition of RET tyrosine kinase by SU5416.

Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. J Mol Endocrinol. 2006 Oct;37(2):199-212. doi: 10.1677/jme.1.01999. J Mol Endocrinol. 2006. PMID: 17032739

9

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Coluccia AM, et al. Among authors: mologni l. EMBO J. 2007 Mar 7;26(5):1456-66. doi: 10.1038/sj.emboj.7601485. Epub 2007 Feb 22. EMBO J. 2007. PMID: 17318191 Free PMC article.

10

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Gunby RH, et al. Among authors: mologni l. Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. doi: 10.2174/187152007784111340. Anticancer Agents Med Chem. 2007. PMID: 18045055 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters